Aosaikang Pharmaceutical

Focus: Aosaikang is an early-stage oncology-focused small molecule pharmaceutical company based in Nanjing, China, founded in 2019. The company is pre-commercial with a pipeline concentrated in Phase 1/2/3 oncology programs.

Oncology

Profile data last refreshed 13h ago · AI intelligence enriched 2w ago

Open Jobs

About Aosaikang Pharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Aosaikang Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ASKG315

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT05554666A Study of ASKG315 in Patients With Advanced Solid Tumors.

Phase 1

Help build intelligence for Aosaikang Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to Phase 3 oncology programs (ASK120067 in NSCLC, ASKC202 in advanced solid tumors) with near-term clinical catalysts
Early-stage company structure may offer broader scope and faster career progression than larger organizations
Access to China's growing oncology market and domestic biotech ecosystem

Watch Out For

Pre-revenue status with unknown funding and cash position creates uncertainty about long-term stability and job security
No active job postings and minimal public presence (zero publications) suggest limited hiring and visibility in the global pharma talent market

Generated by Claude from Aosaikang Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ASKC200

Osteoarthritis, Knee

Phase 1

Clinical Trials (1)

NCT06614608The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain

Phase 1

dexlansoprazole

Safety Issues

Phase 1

Clinical Trials (2)

NCT03011125A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)

Phase 1

NCT03120273A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults（Part 2）

Phase 1

ASKG315

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT05509985A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors

Phase 1

ASKB1202

Healthy

Phase 1

Clinical Trials (1)

NCT03115762Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects

Phase 1

ASKG915

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT05867420A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Phase 1/2

ASKB589

Malignant Solid Tumor

Phase 1/2

Clinical Trials (3)

NCT06206733ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Phase 3

NCT04632108A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2

NCT05632939ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Phase 1/2

ASK120067

Locally Advanced or Metastatic NSCLC

Phase 3

Clinical Trials (5)

NCT04143607ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Phase 3

NCT03502850Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Phase 1/2

NCT05306132Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

Phase 1

+2 more

ASKC202

Advanced Solid Tumor

Phase 3

Clinical Trials (1)

NCT07109531ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 16 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

12 pipeline

Marketed

Pipeline